BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23666221)

  • 1. [Refractory acute myeloid leukemia developed malignancy-associated hemophagocytic lymphohistiocytosis during treatment of invasive fungal infection].
    Yamada A; Moritake H; Sawa D; Shimonodan H; Kojima H; Kamimura S; Nunoi H
    Rinsho Ketsueki; 2013 Apr; 54(4):383-7. PubMed ID: 23666221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
    J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
    Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
    Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukemia cells directly phagocytose blood cells in AML-associated hemophagocytic lymphohistiocytosis: a case report and review of the literature.
    Hatano K; Nagai T; Matsuyama T; Sakaguchi Y; Fujiwara S; Oh I; Muroi K; Ozawa K
    Acta Haematol; 2015; 133(1):98-100. PubMed ID: 25226795
    [No Abstract]   [Full Text] [Related]  

  • 7. Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases: a multicenter study from Turkey.
    Celkan T; Berrak S; Kazanci E; Ozyürek E; Unal S; Uçar C; Yilmaz S; Gürgey A
    Turk J Pediatr; 2009; 51(3):207-13. PubMed ID: 19817262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute myeloid leukemia following etoposide therapy for EBV-associated hemophagocytic lymphohistiocytosis: a case report and a brief review of the literature.
    Pan H; Feng DN; Song L; Sun LR
    BMC Pediatr; 2016 Jul; 16():116. PubMed ID: 27473573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Report of a case with secondary acute promyelocytic leukemia after therapy for hemophagocytic lymphohistiocytosis and review of literature].
    Su Y; Zhou X; Zhang L; Zhang R
    Zhonghua Er Ke Za Zhi; 2013 Dec; 51(12):938-42. PubMed ID: 24495767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute respiratory distress syndrome as an initial presentation of hemophagocytic lymphohistiocytosis after induction therapy for acute myeloid leukemia.
    Nishikawa T; Okamoto Y; Tanabe T; Shinkoda Y; Kodama Y; Kakihana Y; Goto M; Kawano Y
    Pediatr Hematol Oncol; 2011 Apr; 28(3):244-8. PubMed ID: 21083362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93].
    Creutzig U; Zimmermann M; Reinhardt D; Lehrnbecher T
    Klin Padiatr; 2003; 215(3):151-8. PubMed ID: 12778355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy.
    Delavigne K; Bérard E; Bertoli S; Corre J; Duchayne E; Demur C; Mansat-De Mas V; Borel C; Picard M; Alvarez M; Sarry A; Huguet F; Récher C
    Haematologica; 2014 Mar; 99(3):474-80. PubMed ID: 24142998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytosine arabinoside and mitoxantrone induction chemotherapy followed by bone marrow transplantation or chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
    Wells RJ; Gold SH; Krill CE; Cornelius AS; Byrd RL; Ruymann FB; Feusner J; White ML; Cairo MS
    Leukemia; 1994 Oct; 8(10):1626-30. PubMed ID: 7934157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.
    Brito-Babapulle F; Catovsky D; Slocombe G; Newland AC; Marcus RE; Goldman JM; Galton DA
    Cancer Treat Rep; 1987 Feb; 71(2):161-3. PubMed ID: 3467843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
    Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
    Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parvovirus B19-associated hemophagocytic lymphohistiocytosis in a child with precursor B-cell acute lymphoblastic leukemia under maintenance chemotherapy.
    Matsubara K; Uchida Y; Wada T; Iwata A; Yura K; Kamimura K; Nigami H; Fukaya T
    J Pediatr Hematol Oncol; 2011 Oct; 33(7):565-9. PubMed ID: 21617562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia.
    Trifilio SM; Rademaker AW; Newman D; Coyle K; Carlson-Leuer K; Mehta J; Altman J; Frankfurt O; Tallman MS
    Leuk Res; 2012 Apr; 36(4):394-6. PubMed ID: 22172465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.
    Lee SS; Lee JH; Lee JH; Kim DY; Kim SH; Lim SN; Lee YS; Seol M; Ryu SG; Kang YA; Jang S; Park CJ; Chi HS; Yun SC; Lee KH
    Leuk Res; 2009 Apr; 33(4):511-7. PubMed ID: 18819710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.